Ogalvibart Biosimilar – Anti-SARS-CoV-2 Spike RBD mAb – Research Grade from ProteoGenix; catalogue PX-TA1870; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Ogalvibart Biosimilar – Anti-SARS-CoV-2 Spike RBD mAb – Research Grade is a monoclonal antibody (mAb) that has been developed as a potential therapeutic agent against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for the ongoing COVID-19 pandemic. This biosimilar mAb is designed to specifically target the receptor-binding domain (RBD) of the spike protein of the virus, which is essential for viral entry and infection. In this article, we will provide a scientific description of the structure, activity, and potential applications of Ogalvibart Biosimilar – Anti-SARS-CoV-2 Spike RBD mAb.
Ogalvibart Biosimilar – Anti-SARS-CoV-2 Spike RBD mAb is a fully humanized IgG1 antibody, meaning it is derived from human cells and has a structure similar to the antibodies naturally produced in our body. It is composed of two heavy chains and two light chains, which are connected by disulfide bonds to form a Y-shaped molecule. The variable regions of the antibody, responsible for binding to the RBD of the virus, are located at the tips of the Y-shaped structure.
The primary activity of Ogalvibart Biosimilar – Anti-SARS-CoV-2 Spike RBD mAb is to bind to the RBD of the spike protein of SARS-CoV-2. This binding prevents the virus from attaching to and entering human cells, thus inhibiting viral replication and spread. Additionally, this biosimilar mAb can also activate the immune system to target and eliminate virus-infected cells, providing an additional layer of protection against the virus.
Ogalvibart Biosimilar – Anti-SARS-CoV-2 Spike RBD mAb has shown promising results in preclinical studies and is currently being evaluated in clinical trials as a potential treatment for COVID-19. It can be administered as a standalone therapy or in combination with other antiviral agents to enhance its efficacy. This biosimilar mAb is also being investigated for its potential as a prophylactic treatment, providing protection against SARS-CoV-2 infection for individuals at high risk, such as healthcare workers and immunocompromised individuals.
As mentioned earlier, Ogalvibart Biosimilar – Anti-SARS-CoV-2 Spike RBD mAb binds to the RBD of the spike protein of SARS-CoV-2, preventing viral entry and replication. This binding also triggers the immune system to recognize and eliminate virus-infected cells. Additionally, this biosimilar mAb can also block the interaction between the spike protein and the angiotensin-converting enzyme 2 (ACE2) receptor, which is the main receptor used by SARS-CoV-2 to enter human cells.
One of the main advantages of Ogalvibart Biosimilar – Anti-SARS-CoV-2 Spike RBD mAb is its high specificity and affinity for the RBD of the spike protein. This ensures that the antibody effectively targets the virus without affecting healthy cells. Additionally, being a fully humanized antibody, it is less likely to cause adverse immune reactions in patients. Moreover, as a biosimilar mAb, it is expected to have a lower cost compared to other biologic therapies, making it more accessible to a larger population.
In conclusion, Ogalvibart Biosimilar – Anti-SARS-CoV-2 Spike RBD mAb is a promising therapeutic agent for the treatment of COVID-19. Its specific targeting of the RBD of the spike protein and ability to activate the immune system make it a potentially effective treatment option.
ProteoGenix catalogue number PX-TA1870. For research use only.
Target: Ogalvibart Biosimilar – Anti-SARS-CoV-2 Spike RBD mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Ogalvibart Biosimilar – Anti-SARS-CoV-2 Spike RBD mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
